img

Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
Due to the COVID-19 pandemic, the global Monoclonal antibodies (mAbs) Biosimilars market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Erythropoietin (EPO) accounting for % of the Monoclonal antibodies (mAbs) Biosimilars global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Anti-Cancer segment is altered to an % CAGR throughout this forecast period.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Monoclonal antibodies (mAbs) Biosimilars market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Monoclonal antibodies (mAbs) Biosimilars market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Monoclonal antibodies (mAbs) Biosimilars market. Readers of the report can become informed about current and future trends of the global Monoclonal antibodies (mAbs) Biosimilars market and how they will impact market growth during the forecast period.



By Company


Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others

Segment by Application


Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Monoclonal antibodies (mAbs) Biosimilars in global and regional level.
Chapter 3Detailed analysis of Monoclonal antibodies (mAbs) Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal antibodies (mAbs) Biosimilars revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2034)
2.2 Monoclonal antibodies (mAbs) Biosimilars Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2018-2024)
2.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Monoclonal antibodies (mAbs) Biosimilars Countries Ranking by Market Size
3 Monoclonal antibodies (mAbs) Biosimilars Competitive by Company
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players
3.1.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2018-2024)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2018-2024)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
3.5 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars Head office and Area Served
3.6 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Product and Application
3.7 Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Revenue by Type (2018-2024)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Revenue by Type (2024-2034)
5 Global Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2018-2024)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2034)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2034)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2034)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2034)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024)
8.2 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2034)
8.3 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2034)
8.4 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2034)
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2034)
9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024)
10.2 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2034)
10.3 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2034)
10.4 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Biocon
11.1.1 Biocon Company Details
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.1.5 Biocon Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.1.6 Biocon Recent Development
11.2 Celltrion
11.2.1 Celltrion Company Details
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.2.5 Celltrion Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.2.6 Celltrion Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Details
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.3.5 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.3.6 Dr. Reddy's Laboratories Recent Development
11.4 Hospira
11.4.1 Hospira Company Details
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.4.5 Hospira Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.4.6 Hospira Recent Development
11.5 3SBio
11.5.1 3SBio Company Details
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.5.5 3SBio Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.5.6 3SBio Recent Development
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Details
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.6.5 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.6.6 Accord Healthcare Recent Development
11.7 AET Biotech
11.7.1 AET Biotech Company Details
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.7.5 AET Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.7.6 AET Biotech Recent Development
11.8 Allergan
11.8.1 Allergan Company Details
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.8.5 Allergan Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.8.6 Allergan Recent Development
11.9 Amega Biotech
11.9.1 Amega Biotech Company Details
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
11.9.5 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.9.6 Amega Biotech Recent Development
12 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
12.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
12.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
12.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
12.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Erythropoietin (EPO)
Table 3. Key Players of Human Growth Hormone (HGH)
Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 5. Key Players of Monoclonal Antibody (mAb)
Table 6. Key Players of Insulin
Table 7. Key Players of Interferon (IFN)
Table 8. Key Players of Others
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2018-2024)
Table 16. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Table 17. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2018-2024)
Table 19. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Headquarters and Area Served
Table 20. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Product and Application
Table 21. Global Key Players of Monoclonal antibodies (mAbs) Biosimilars, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2024)
Table 25. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Table 27. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2024)
Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Table 31. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024) & (US$ Million)
Table 32. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 33. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 34. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 35. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 37. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 38. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 39. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024) & (US$ Million)
Table 40. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 41. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 42. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 43. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 44. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 45. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 46. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 47. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024) & (US$ Million)
Table 48. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 49. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 50. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 51. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 52. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 53. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2018-2024) & (US$ Million)
Table 54. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 55. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024) & (US$ Million)
Table 56. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 57. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 58. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 59. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 60. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 61. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 62. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2021-2024) & (US$ Million)
Table 64. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 66. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 68. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 69. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2018-2024) & (US$ Million)
Table 70. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 71. Biocon Company Details
Table 72. Biocon Business Overview
Table 73. Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 74. Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 75. Biocon Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 76. Biocon Recent Development
Table 77. Celltrion Company Details
Table 78. Celltrion Business Overview
Table 79. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 80. Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 81. Celltrion Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 82. Celltrion Recent Development
Table 83. Dr. Reddy's Laboratories Company Details
Table 84. Dr. Reddy's Laboratories Business Overview
Table 85. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 86. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 87. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 88. Dr. Reddy's Laboratories Recent Development
Table 89. Hospira Company Details
Table 90. Hospira Business Overview
Table 91. Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 92. Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 93. Hospira Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 94. Hospira Recent Development
Table 95. 3SBio Company Details
Table 96. 3SBio Business Overview
Table 97. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 98. 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 99. 3SBio Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 100. 3SBio Recent Development
Table 101. Accord Healthcare Company Details
Table 102. Accord Healthcare Business Overview
Table 103. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 104. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 105. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 106. Accord Healthcare Recent Development
Table 107. AET Biotech Company Details
Table 108. AET Biotech Business Overview
Table 109. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 110. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 111. AET Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 112. AET Biotech Recent Development
Table 113. Allergan Company Details
Table 114. Allergan Business Overview
Table 115. Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 116. Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 117. Allergan Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 118. Allergan Recent Development
Table 119. Amega Biotech Company Details
Table 120. Amega Biotech Business Overview
Table 121. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 122. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024) & (US$ Million)
Table 123. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 124. Amega Biotech Recent Development
Table 125. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 126. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 127. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 128. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Monoclonal antibodies (mAbs) Biosimilars Product Picture
Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2022 VS 2034
Figure 4. Erythropoietin (EPO) Features
Figure 5. Human Growth Hormone (HGH) Features
Figure 6. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 7. Monoclonal Antibody (mAb) Features
Figure 8. Insulin Features
Figure 9. Interferon (IFN) Features
Figure 10. Others Features
Figure 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2022 VS 2034
Figure 13. Anti-Cancer
Figure 14. Anti-Inflammatory/Autoimmune
Figure 15. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Size 2018-2034 (US$ Million)
Figure 18. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Market Share by Region: 2022 VS 2034
Figure 19. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region in 2018 VS 2022
Figure 20. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share Forecast by Region (2024-2034)
Figure 21. Global Top 10 Monoclonal antibodies (mAbs) Biosimilars Countries Ranking by Market Size (US$ Million) in 2022
Figure 22. Global Monoclonal antibodies (mAbs) Biosimilars Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 23. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2022
Figure 24. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Figure 25. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
Figure 26. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2022
Figure 27. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2034)
Figure 28. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2034)
Figure 29. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2018-2034)
Figure 30. U.S. Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 31. Canada Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 32. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2022
Figure 33. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2034)
Figure 34. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2034)
Figure 35. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2018-2034)
Figure 36. Germany Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 37. France Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 38. U.K. Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 39. Italy Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 40. Russia Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 41. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2022
Figure 42. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2034)
Figure 43. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2034)
Figure 44. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Region (2018-2034)
Figure 45. China Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 46. Japan Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 47. South Korea Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 48. India Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 49. Australia Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 50. Taiwan Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 51. Indonesia Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 52. Thailand Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 53. Malaysia Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 54. Philippines Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 55. Vietnam Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 56. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2022
Figure 57. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2034)
Figure 58. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2034)
Figure 59. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2018-2034)
Figure 60. Mexico Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 61. Brazil Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 62. Argentina Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 63. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2022
Figure 64. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2034)
Figure 65. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2034)
Figure 66. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2018-2034)
Figure 67. Turkey Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 68. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 69. U.A.E Monoclonal antibodies (mAbs) Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 70. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 71. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 72. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 73. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 74. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 75. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 76. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 77. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 78. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed